ovin’s r&d partnership fund - wintertech development program supports ontario small and medium enterprises (smes) and their partners to validate, test, prototype, and demonstrate new products and technologies designed to meet the unique demands of winter weather conditions.

wintertech development leverages the strengths and innovative capabilities of ontario smes in the automotive and mobility sector and our unique winter weather conditions to establish the province as a test bed for mobility products and services in severe winter weather conditions.

because of ovin's wintertech development program, ontario is a global leader in the commercialization of new winter-ready mobility technologies and solutions.

wintertech development supports projects related to technology/product/service validation, testing, demonstration and prototyping of mobility products and services in severe winter weather conditions in the following priority areas:

• mass light vehicles, such as cars, trucks, and vans
• heavy duty vehicles, including commercial vehicles, trucks, buses, recreational vehicles (rvs), and others used for goods movement
• transportation infrastructure
• intelligent transportation systems (its)
• transit-supportive systems and vehicles

the fy22 tscrp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website. 

applications submitted to the fy22 tscrp exploration – hypothesis development award or idea development award must address one or more of the following focus areas:

• understanding and treating the features of tsc-associated neuropsychiatric disorders (tand) and reducing their impact, including pharmacological and behavioral interventions
• strategies for eradicating tumors or other pathogenic lesions associated with tsc and tsc-associated lymphangioleiomyomatosis (lam), including gaining a deeper mechanistic understanding of tsc signaling pathways and tumor microenvironment
• preventing epilepsy, improving treatment, and mitigating neurodevelopmental outcomes associated with tsc-related seizures

applications submitted to the fy22 tscrp clinical translational research award must address one or more of the following focus areas:

• understanding and treating the features of tsc-associated neuropsychiatric disorders (tand) and reducing their impact, including pharmacological, behavioral, and surgical interventions
• strategies for eradicating tumors or other pathogenic lesions associated with tsc and tsc-associated lymphangioleiomyomatosis (lam, including gaining a deeper mechanistic understanding of tsc signaling pathways and tumor microenvironment
• preventing epilepsy, improving treatment, and mitigating neurodevelopmental outcomes associated with tsc-related seizures

funding opportunities- fy21 tscrp, congressionally directed medical research programs (cdmrp), us dod (army.mil)

exploration – hypothesis development award – letter of intent due june 30, 2022

investigators at all academic levels (or equivalent), including postdoctoral fellows

supports the initial exploration of innovative, high-risk, high[1]gain, and potentially groundbreaking concepts in the tuberous sclerosis complex (tsc) research field.

• projects involving human subjects or human biological substances must be exempt under title 32 of the code of regulations, part 219.104(d) (32 cfr 219.104(d)) or eligible for expedited review under 21 cfr 56.110.

• preliminary data not required.

• clinical trials not allowed.

the maximum period of performance is 2 years.

• the maximum allowable funding for the entire period of performance is $150,000 in direct costs.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

idea development award – letter of intent june 30, 2022

established investigators: independent investigators at or above the level of assistant professor (or equivalent) or new-to-the-field investigator: independent investigators at or below the level of assistant professor (or equivalent) or established investigators in an area other than tsc at or above the level of assistant professor seeking to transition to a career in tsc

promotes ideas that have the potential to yield high-impact findings and new avenues of investigation.

• preliminary data expected.

• clinical trials not allowed.

• new-to-the-field investigator option supports the continued development of promising independent investigators that are early in their faculty appointments and/or the transition of established investigators from other research fields into a career in the field of tsc research.

• applications from new-to-the-field investigators and established investigators will compete separately.

the maximum period of performance is 3 years.

• the maximum allowable funding for the entire period of performance is $500,000 in direct costs.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

clinical translational research award – letter of intent due june 30, 2022

independent investigators at or above the level of assistant professor (or equivalent)

supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including, diagnosis, prognosis, or treatment of tsc.

• applications may include correlative studies that are associated with a completed clinical trial.

• supports studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of pharmacokinetics/ pharmacodynamics.

• applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research.

• preclinical studies may be appropriate but must include a clinical component.

• projects that are exploratory and/or strictly animal research will not be considered for funding.

• collaborations between clinicians and research scientists are strongly encouraged.

• preliminary data required.

• the maximum period of performance is 3 years.

• the maximum allowable funding for the entire period of performance is $1,000,000 in direct costs.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the tscrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

for more information, please contact jill sherman, international research facilitator, at intl.research@lakeheadu.ca.

the fy22 defense appropriations act provides funding for the peer reviewed cancer research program (prcrp) to support innovative, high-impact cancer research.  the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 prcrp funding opportunity announcements for the following award mechanisms will be posted on the grants.gov website. 

congressionally directed topic areas:  the fy22 prcrp appropriation will provide funds for research into cancers not addressed in the other cdmrp cancer programs (https://cdmrp.army.mil/researchprograms).  to be considered for funding, applications for the fy22 prcrp must address at least one of the fy22 prcrp topic areas as directed by congress.  research applications in the areas of breast, kidney, lung, prostate, pancreatic, ovarian, and rare cancer or melanoma are prohibited and will not be accepted.  the inclusion of the individual rare cancer research program shall not prohibit the prcrp from funding the below-mentioned cancers or cancer subtypes that may be rare by definition.

the fy22 prcrp topic areas are:

the fy22 prcrp military health focus areas are listed below:

it is central to the vision and mission of the prcrp that applications address how the proposed research is related to military health, mission readiness, and the cancer health needs of both deployed and non-deployed military personnel, their dependents, veterans, and other military beneficiaries (i.e., family members of retirees).  the fy22 prcrp requires all applications to answer at least one of the following military health focus areas:

• environmental/exposure risk factors associated with cancer

• ·        gaps in cancer research that may affect mission readiness:

○       gaps in cancer prevention, early detection/diagnosis, prognosis, and/or treatment that may affect the general population but have a particularly profound impact on the health and well-being of military service members, veterans, and their beneficiaries

○       gaps in quality of life and/or survivorship that may affect the general population but have a particularly profound impact on the health and well-being of military service members, veterans, and their beneficiaries

fy22 prcrp overarching challenges

the prcrp has developed a strategy to address multiple issues in cancer research over the spectrum of different cancer topics considered for funding.  these overarching challenges are critical gaps in cancer research, care, and/or patient outcomes that, if addressed, will advance the mission readiness of u.s. military members affected by cancer and will improve quality of life by decreasing the burden of cancer on service members, their families, veterans, and the american public.  to reference the prcrp overarching challenges, see https://cdmrp.army.mil/prcrp.

press release: 2022 peer reviewed cancer research program, congressionally directed medical research program (army.mil)

idea award – preproposal due may 25, 2022

independent investigator with a faculty-level appointment (or equivalent).

preproposal is required; application submission is by invitation only.

• supports innovative, untested, high-risk/ potentially high-reward concepts, theories, paradigms, and/or methods in cancer research.

• emphasis on innovation.

• must address at least one of the fy22 prcrp topic areas.

• must address at least one of the fy22 prcrp military health focus areas.

• must address at least one of the fy22 prcrp overarching challenges.

• preliminary data are not required.

• clinical trials are not allowed.

the maximum allowable funding for the entire period of performance is $400,000 for direct costs.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• the maximum period of performance is 2 years.

impact award – preproposal due may 25, 2022

independent investigators at or above the level of assistant professor (or equivalent) are eligible to submit an application.

preproposalis required; application submission is by invitation only.

• supports hypothesis-driven, high impact research.

• supports research projects that, if successfully addressed, have the potential to make a near-term, major impact on one of the fy22 prcrp topic areas.

• must address at least one of the fy22 prcrp topic areas.

• must address at least one of the fy22 prcrp military health focus areas.

• must address at least one of the fy22 prcrp overarching challenges.

• preliminary data are required.

• clinical trials are allowed.

the maximum allowable funding for the entire period of performance is $1,000,000 for direct costs.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• the maximum period of performance is 3 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements that will be available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism can be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the prcrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk

301-682-5507
help@ebrap.org

for more information, please contact jill sherman, international research facilitator, at intl.research@lakeheadu.ca.

the fy22 defense appropriations act provides funding for the peer reviewed cancer research program (prcrp) to support innovative, high-impact cancer research.  the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 prcrp funding opportunity announcements for the following award mechanisms will be posted on the grants.gov website. 

congressionally directed topic areas:  the fy22 prcrp appropriation will provide funds for research into cancers not addressed in the other cdmrp cancer programs (https://cdmrp.army.mil/researchprograms).  to be considered for funding, applications for the fy22 prcrp must address at least one of the fy22 prcrp topic areas as directed by congress.  research applications in the areas of breast, kidney, lung, prostate, pancreatic, ovarian, and rare cancer or melanoma are prohibited and will not be accepted.  the inclusion of the individual rare cancer research program shall not prohibit the prcrp from funding the below-mentioned cancers or cancer subtypes that may be rare by definition.

the fy22 prcrp topic areas are:

the fy22 prcrp military health focus areas are listed below:

it is central to the vision and mission of the prcrp that applications address how the proposed research is related to military health, mission readiness, and the cancer health needs of both deployed and non-deployed military personnel, their dependents, veterans, and other military beneficiaries (i.e., family members of retirees).  the fy22 prcrp requires all applications to answer at least one of the following military health focus areas:

• environmental/exposure risk factors associated with cancer

• ·        gaps in cancer research that may affect mission readiness:

○       gaps in cancer prevention, early detection/diagnosis, prognosis, and/or treatment that may affect the general population but have a particularly profound impact on the health and well-being of military service members, veterans, and their beneficiaries

○       gaps in quality of life and/or survivorship that may affect the general population but have a particularly profound impact on the health and well-being of military service members, veterans, and their beneficiaries

fy22 prcrp overarching challenges

the prcrp has developed a strategy to address multiple issues in cancer research over the spectrum of different cancer topics considered for funding.  these overarching challenges are critical gaps in cancer research, care, and/or patient outcomes that, if addressed, will advance the mission readiness of u.s. military members affected by cancer and will improve quality of life by decreasing the burden of cancer on service members, their families, veterans, and the american public.  to reference the prcrp overarching challenges, see https://cdmrp.army.mil/prcrp.

press release: 2022 peer reviewed cancer research program, congressionally directed medical research program (army.mil)

convergent science cancer consortium development award – letter of intent due august 17, 2022

pi for coordinating center (consortium director): investigators at or above the level of associate professor (or equivalent); must have a proven record of accomplishment of leading and scientific ability to direct and oversee a multi[1]institutional research effort. co-pi for the research site: investigators at or above the level of assistant professor (or equivalent); must have a proven record of accomplishment of collaboration

letter of intent is required. an invitation to submit a full application is not required.

• supports novel approaches to ending cancer through convergent science research.

• emphasis is on the development of a convergent science infrastructure – coordinating center.

• proof of principle (convergent science) research projects support.

• must address at least one of the fy22 prcrp military health focus areas.

• must address at least three different fy22 prcrp topic areas.

• must address at one of the fy22 prcrp overarching challenges.

• clinical trials are not allowed.

• ·        the maximum allowable funding for the entire period of performance is $2,500,000 for direct costs.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• the maximum period of performance is 4 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements that will be available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism can be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the prcrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk

301-682-5507
help@ebrap.org

for more information, please contact jill sherman, international research facilitator, at intl.research@lakeheadu.ca.

the fy22 defense appropriations act provides funding for the peer reviewed cancer research program (prcrp) to support innovative, high-impact cancer research.  the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 prcrp funding opportunity announcements for the following award mechanisms will be posted on the grants.gov website. 

congressionally directed topic areas:  the fy22 prcrp appropriation will provide funds for research into cancers not addressed in the other cdmrp cancer programs (https://cdmrp.army.mil/researchprograms).  to be considered for funding, applications for the fy22 prcrp must address at least one of the fy22 prcrp topic areas as directed by congress.  research applications in the areas of breast, kidney, lung, prostate, pancreatic, ovarian, and rare cancer or melanoma are prohibited and will not be accepted.  the inclusion of the individual rare cancer research program shall not prohibit the prcrp from funding the below-mentioned cancers or cancer subtypes that may be rare by definition.

the fy22 prcrp topic areas are:

the fy22 prcrp military health focus areas are listed below:

it is central to the vision and mission of the prcrp that applications address how the proposed research is related to military health, mission readiness, and the cancer health needs of both deployed and non-deployed military personnel, their dependents, veterans, and other military beneficiaries (i.e., family members of retirees).  the fy22 prcrp requires all applications to answer at least one of the following military health focus areas:

• environmental/exposure risk factors associated with cancer

• ·        gaps in cancer research that may affect mission readiness:

○       gaps in cancer prevention, early detection/diagnosis, prognosis, and/or treatment that may affect the general population but have a particularly profound impact on the health and well-being of military service members, veterans, and their beneficiaries

○       gaps in quality of life and/or survivorship that may affect the general population but have a particularly profound impact on the health and well-being of military service members, veterans, and their beneficiaries

fy22 prcrp overarching challenges

the prcrp has developed a strategy to address multiple issues in cancer research over the spectrum of different cancer topics considered for funding.  these overarching challenges are critical gaps in cancer research, care, and/or patient outcomes that, if addressed, will advance the mission readiness of u.s. military members affected by cancer and will improve quality of life by decreasing the burden of cancer on service members, their families, veterans, and the american public.  to reference the prcrp overarching challenges, see https://cdmrp.army.mil/prcrp.

press release: 2022 peer reviewed cancer research program, congressionally directed medical research program (army.mil)

behavioral health science award – letter of intent due july 12, 2022

independent investigator with a faculty-level appointment (or equivalent).

• ·    letter of intent is required. an invitation to submit a full application is not required.
• ·    supports high-reward concepts that spans the spectrum of behavioral health science including prevention, survivorship, quality of life, and psychosocial research related to cancer.
• ·    must address at least one of the fy22 prcrp topic areas.
• ·    must address at least one of the fy22 prcrp military health focus areas.
  • ·    must address at least one of the fy22 prcrp overarching challenges.
  • ·    preliminary data required.
  • ·    pilot clinical trials are allowed.
  • ·    the maximum allowable funding for the entire period of performance is $1,000,000 for direct costs.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• the maximum period of performance is 4 years.

career development award – fellow option – letter of intent due july 12, 2022

principal investigator (pi): independent investigators at or above the level of research assistant professor or instructor (or equivalent) and within 7 years after completion of their terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline.

career guide: investigators at or above the level of associate professor (or equivalent); must have a proven publication and funding record in cancer research.

letter of intent is required. an invitation to submit a full application is not required.

• supports early-career investigators to conduct impactful research with the mentorship of an experienced cancer researcher.

• must address at least one of the fy22 prcrp topic areas.

• must address at least one of the fy22 prcrp military health focus areas.

• must address at least one of the fy22 prcrp overarching challenges.

• preliminary data are not required.

• clinical trials are not allowed.

the maximum allowable funding for the entire period of performance is $400,000 for direct costs.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• the maximum period of performance is 3 years.

career development award –  virtual cancer center scholar option – letter of intent due july 12, 2022

• ·    pi: independent investigators at or above the level of assistant professor or instructor (or equivalent) on tenure track and within 7 years after completion of their terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline.
• ·    career guide: investigators at or above the level of associate professor (or equivalent); must have a proven publication and funding record in cancer research.
• ·    letter of intent is required. an invitation to submit a full application is not required.
• ·    supports the addition of new early-career investigators (scholars) to the unique, interactive virtual cancer center focused on fostering the next generation of cancer researchers. •
• ·     the scholar will be required to interact within the virtual cancer center and with the cancer center director and deputy director.
• ·     the scholar option provides intensive mentoring, national networking, and a peer group for junior faculty. • scholars must demonstrate significant accomplishments.
• ·     a career guide – an experienced cancer researcher with cancer funding – is required. • the career guide is not required to be at the same institution as the scholar.
• ·     must address at least one of the fy22 prcrp topic areas.
• ·    must address at least one of the fy22 prcrp military health focus areas.
• ·    preliminary data are not required. • clinical trials are not allowed.
• ·    the maximum allowable funding for the entire period of performance is $800,000 for direct costs.
• ·    indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·    the maximum period of performance is 4 years.

translational team science award – letter of intent due july 12, 2022

at least two, and a maximum of three, pis must partner in one overarching correlative or translational research study.

at least one of the pis is encouraged to be a military or us department of veterans affairs investigator.

• ·    letter of intent is required. an invitation to submit a full application is not required.
• ·    emphasizes multi-pi, multidisciplinary collaborations.
• ·    supports translational studies associated with an ongoing or completed clinical trial that can lead to a future clinical trial or clinical application in cancer research.
• ·    not intended to support high-throughput screenings, sequencing, etc.
• ·    must address at least one of the fy22 prcrp topic areas.
• ·    must address at least one of the fy22 prcr overarching challenges.
  • ·    must address at least one of the fy22 prcrp military health focus areas.
  • ·    preliminary data are required.
  • ·    clinical trials are allowed.
  • ·        the maximum allowable funding for the entire period of performance is $2,500,000 for direct costs.
  • ·        indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
  • the maximum period of performance is 4 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements that will be available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism can be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the prcrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk

301-682-5507
help@ebrap.org

for more information, please contact jill sherman, international research facilitator, at intl.research@lakeheadu.ca.

alberta’s firefighters, police officers, paramedics, sheriffs, corrections officers and emergency health care workers often deal with stressful, dangerous and traumatic situations. this stress has a negative impact on first responders and emergency health care workers. they often experience post-traumatic stress injuries (ptsi) at significantly higher rates than the general population.

the supporting psychological health in first responders (sphifr) grant program has 2 separate funding streams:

• stream 1 (services) provides funding for non-profit organizations that provide services to first responders and emergency health care workers living with or at risk for ptsi.
• stream 2 (research) provides funding to researchers engaged in applied research that generates evidence on prevention or intervention for first responders and emergency health care workers living with or at risk for ptsi.

the fy22 defense appropriations act is anticipated to provide funding for the scirp to support innovative, high-impact spinal cord injury (sci) research.¹  the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 scirp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website. 

applications submitted to the fy22 scirp must address one or more of the following focus areas^†:

• ·        preserving and protecting spinal cord tissue at time of injury for improved neurologic outcomes
• ·        identifying and validating biomarkers for diagnosis, prognosis, and for evaluation of treatment efficacies
• ·        developing, testing, and validating promising interventions to address bowel, genitourinary, neuropathic pain, cardiopulmonary, or autonomic dysfunction in people with sci
• ·        investigating psychosocial issues relevant to people with sci, their families, and/or their care-partners
• ·        rehabilitation and regeneration—maximizing the function of the residual neural circuitry, including harnessing neuroplasticity and recovery to improve function after sci

funding opportunities-fy22 scirp, congressionally directed medical research programs (cdmrp), us dod (army.mil)

clinical trial award – preproposal due may 23, 2022

principal investigator (pi): investigators at all academic levels (or equivalent)

optional early-career partnering pi:

an independent, early-career investigator within 10 years after completion of terminal degree

• ·        preproposal is required; application submission is by invitation only.

translational research award – preproposal due may 23, 2022

pi: investigators at all academic levels (or equivalent)

optional early-career partnering pi:

an independent, early-career investigator within 10 years after completion of terminal degree

• ·        preproposal is required; application submission is by invitation only.
• ·        funds studies that accelerate the movement of promising ideas in sci research into clinical applications.

• community collaborations in research: applications are expected to name at least one community partner (e.g., sci lived experience consultant, representative of community-based organization) who will provide advice and consultation throughout the planning and implementation of the research project.

• preliminary data required.

• the scirp translational research award may include a pilot clinical trial only as a part of the proposed research where limited clinical testing of a novel intervention or device is necessary to inform the next step in the continuum of translational research.

• early-career partnering pi option

the maximum allowable funding for the entire period of performance is $1.25m for direct costs.

• early-career partnering pi option: maximum allowable funding for the entire period of performance is $1.35m for direct costs.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• the maximum period of performance is 3 years.

investigator-initiated research award – preproposal due may 23, 2021

pi: investigators at all academic levels (or equivalent)

optional early-career partnering pi:

an independent, early-career investigator within 10 years after completion of his/her terminal degree

• ·        preproposal is required; application submission is by invitation only.

funds research that has the potential to make an important contribution to sci research, patient care, and/or quality of life.

• studies focused exclusively on target identification are discouraged.

• preliminary data required.

• clinical trials are not allowed.

• early-career partnering pi option

the maximum allowable funding for the entire period of performance is $0.50m for direct costs.

• early-career partnering pi option: maximum allowable funding for the entire period of performance is $0.60m for direct costs.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• the maximum period of performance is 3 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the scirp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

¹ funding is provided through the fy22 appropriation for peer-reviewed spinal cord research

for more information, please contact jill sherman, international research facilitator, at intl.research@lakeheadu.ca .

fisheries and oceans canada (dfo) provides funding to build expertise in ocean and freshwater science and technology in areas that support the mission of the department to increase our understanding of ocean and freshwater environments. through this, we seek to better protect, sustain and restore fisheries resources as well as the aquatic ecosystems that support them.

the department is seeking projects that deliver scientific research and related scientific activities that support evidence-based decision making and public understanding about the health of marine and freshwater ecosystems. related scientific activities complement and extend scientific research by contributing to the generation, dissemination and application of scientific and technological knowledge. examples of this include:

• data collection and integration
• ocean and freshwater monitoring
• data analyses
• modelling and hypothesis testing
• scientific capacity building (indigenous recipients only)
• communication of science in support of ocean literacy